Treatment of dementia

Lars Ittner; Yazi Diana Ke

Treatment of dementia

Lars Ittner (Inventor), Yazi Diana Ke (Inventor)

Macquarie University

Research output: Patent

Abstract

Provided herein are methods for treating, delaying the onset of, or ameliorating at least one symptom of, dementia associated with β-amyloid (Aβ) accumulation, and for improving memory in subjects suffering from dementia associated with Aβ accumulation, comprising administering to subjects in need thereof an effective amount of an inhibitor of LIMK1, wherein the inhibitor comprises a compound of Formula (I) as defined herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for reducing Aβ toxicity in neurons, comprising exposing neurons to an effective amount of an inhibitor of LIMK1, wherein the inhibitor comprises a compound of Formula (I) as defined herein, or a pharmaceutically acceptable salt thereof.

Original language	English
Patent number	WO2021056071
IPC	A61P 25/ 28 A I,A61K 31/519
Priority date	25/09/19
Publication status	Submitted - 1 Apr 2021

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=AU359948067

Treatment of dementia
Ittner, L. (Inventor) & Ke, Y. D. (Inventor), 3 Aug 2022, (Submitted) IPC No. A61P 25/ 28 A I, A61K31/519, Patent No. EP4034124, 25 Sept 2020, Priority date 25 Sept 2020, Priority No. WO2020AU51022
Research output: Patent
Treatment of dementia
Ittner, L. (Inventor) & Ke, Y. D. (Inventor), 15 Sept 2022, (Submitted) IPC No. A61P 25/ 28 A I, A61K 31/519, Patent No. US2022288082, Priority date 25 Sept 2020, Priority No. WO2020AU51022
Research output: Patent
Treatment of dementia
Ittner, L. (Inventor) & Ke, Y. D. (Inventor), 19 May 2022, (Submitted) IPC No. A61P 25/ 28 A I, A61K 31/519, Patent No. AU2020351830, 25 Sept 2020, Priority date 25 Sept 2020, Priority No. WO2020AU51022
Research output: Patent

Cite this

@misc{4b8ebc8bced245f6b6357f65811c16a0,

title = "Treatment of dementia",

abstract = "Provided herein are methods for treating, delaying the onset of, or ameliorating at least one symptom of, dementia associated with β-amyloid (Aβ) accumulation, and for improving memory in subjects suffering from dementia associated with Aβ accumulation, comprising administering to subjects in need thereof an effective amount of an inhibitor of LIMK1, wherein the inhibitor comprises a compound of Formula (I) as defined herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for reducing Aβ toxicity in neurons, comprising exposing neurons to an effective amount of an inhibitor of LIMK1, wherein the inhibitor comprises a compound of Formula (I) as defined herein, or a pharmaceutically acceptable salt thereof.",

author = "Lars Ittner and Ke, \{Yazi Diana\}",

year = "2021",

month = apr,

day = "1",

language = "English",

type = "Patent",

note = "WO2021056071; A61P 25/ 28 A I,A61K 31/519",

}

TY - PAT

T1 - Treatment of dementia

AU - Ittner, Lars

AU - Ke, Yazi Diana

PY - 2021/4/1

Y1 - 2021/4/1

N2 - Provided herein are methods for treating, delaying the onset of, or ameliorating at least one symptom of, dementia associated with β-amyloid (Aβ) accumulation, and for improving memory in subjects suffering from dementia associated with Aβ accumulation, comprising administering to subjects in need thereof an effective amount of an inhibitor of LIMK1, wherein the inhibitor comprises a compound of Formula (I) as defined herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for reducing Aβ toxicity in neurons, comprising exposing neurons to an effective amount of an inhibitor of LIMK1, wherein the inhibitor comprises a compound of Formula (I) as defined herein, or a pharmaceutically acceptable salt thereof.

AB - Provided herein are methods for treating, delaying the onset of, or ameliorating at least one symptom of, dementia associated with β-amyloid (Aβ) accumulation, and for improving memory in subjects suffering from dementia associated with Aβ accumulation, comprising administering to subjects in need thereof an effective amount of an inhibitor of LIMK1, wherein the inhibitor comprises a compound of Formula (I) as defined herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for reducing Aβ toxicity in neurons, comprising exposing neurons to an effective amount of an inhibitor of LIMK1, wherein the inhibitor comprises a compound of Formula (I) as defined herein, or a pharmaceutically acceptable salt thereof.

M3 - Patent

M1 - WO2021056071

ER -

Treatment of dementia

Abstract

Access to Document

Fingerprint

Research output